A New Era in the Prevention and
Management of Cytomegalovirus (CMV) Infection in Transplant
Recipients: Assessing the Evidence in Real-World Applications
A continuing medical education
activity provided by NAMCP and AAMCN
A New Era in the Prevention and Management of CMV Infection is a
two-part webinar series
This is Part 2 of the series focusing on management of
Cytomegalovirus (CMV) Infection
This activity is an archive from the webinar held July 28, 2021
This activity is valid from September 1, 2021 – September 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Cytomegalovirus (CMV) infection remains a frequent complication in
hematopoietic stem cell transplantation (HSCT) and solid organ
transplantation (SOT) recipients. In addition to causing a variety
of end-organ diseases, CMV infection is also associated with
rejection after SOT and with graft versus host disease (GVHD) after
HSCT. Antiviral prophylaxis is effective against direct and indirect
effects of CMV infection. Preemptive therapy, more commonly used
after HSCT, is based on surveillance, and targets therapy to
patients at highest risk. Novel antiviral therapies with different
mechanisms of action have recently become available giving
healthcare professionals new options in the management of this
infection. This program will take a look at those advances and
provide up to date strategies for the management of CMV infection.
This webinar series on the evolving role of novel therapies in CMV
infection management will take a close look at recent guideline
updates, clinical data, and strategies for the prevention and
management of CMV.
Upon completion of this
activity, participants will be able to:
Describe patient populations and
procedures associated with the greatest risk for negative
outcomes due to CMV infection or reactivation
Incorporate recent evidence into
practice regarding the use of prophylactic and preemptive
measures to prevent cytomegalovirus (CMV) disease in transplant
Differentiate conventional versus
newer antiviral therapies in terms of safety and efficacy,
ability to reduce CMV reactivation, and improvement of survival
in transplant recipients
Evaluate the optimal duration of
prophylactic or preemptive treatment in patients at risk for CMV
Review recent guideline statements
and expert recommendations for CMV infection management,
prevention, and follow-up care
||Roy F Chemaly, MD, MPH,
has received research/grant support from Merck, Chimerix,
Takeda/Shire, Oxford Immunotec, Viracor, and Novartis.
He serves on the as a consultant, speaker, and on an
advisory board for Merck, Chimerix, Takeda/Shire, Oxford
Immunotec, and Clinigen.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue